<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34186156</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>28</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0542</ISSN><JournalIssue CitedMedium="Internet"><Volume>237</Volume><PubDate><Year>2021</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Immunology letters</Title><ISOAbbreviation>Immunol Lett</ISOAbbreviation></Journal><ArticleTitle>Relevance of autoantibody profile with HLA-DRB1 and -DQB1 alleles in a group of Iranian systemic lupus erythematosus patients.</ArticleTitle><Pagination><StartPage>11</StartPage><EndPage>16</EndPage><MedlinePgn>11-16</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.imlet.2021.06.004</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0165-2478(21)00098-5</ELocationID><Abstract><AbstractText Label="BACKGROUND">One of the most relevant genetic components in systemic lupus erythematosus (SLE) is human leukocyte antigen (HLA) gene complex which plays a central role in autoimmune responses. This study aimed to explore the associations of HLA-DRB1/-DQB1 alleles and haplotypes with SLE risk and the appearance of autoantibodies in SLE disease.</AbstractText><AbstractText Label="METHODS">A total of 127 SLE patients and 153 ethnically matched healthy controls were enrolled. HLA-DRB1 and HLA-DQB1 alleles were determined by PCR-SSP method and then HLA alleles and haplotypes frequencies were compared between two groups and among the patients in terms of autoantibodies spectrum.</AbstractText><AbstractText Label="RESULTS">We found that HLA-DRB1*03 and HLA-DRB1*16 alleles were significantly associated with increased risk (P&#xa0;=&#xa0;0.008, P<sub>C</sub>=0.05 and P&#xa0;=&#xa0;0.002, P<sub>C</sub>=0.02 respectively) and DRB1*01 conferred a potential protective role for disease (P&#xa0;=&#xa0;0.03, P<sub>C</sub>=0.13). Similar associations were observed at haplotype level; DRB1*03~DQB1*02 (OR1.91,P&#xa0;=&#xa0;0.01, P<sub>C</sub>=0.08), DRB1*16~DQB1*05 (OR3.65,P&#xa0;=&#xa0;0.004,P<sub>C</sub>=0.06) and DRB1*01~DQB1*05 (OR0.36,P&#xa0;=&#xa0;0.04, P<sub>C</sub>=0.22). Remarkably, we observed significantly associations of DRB1*03 with the appearance of anti-SSA/Ro (P<sub>C</sub>=0.02), anti-SSB/La (P<sub>C</sub>=0.002) and anti-coagulant (P&#xa0;=&#xa0;0.007), DRB1*15 with anti-SSA/Ro (P<sub>C</sub>=0.04), DRB1*16 with anti-Sm (P<sub>C</sub>=0.02), DRB1*04 with anti-&#x3b2;2gpI (P<sub>C</sub>=3&#xa0;*&#xa0;10<sup>-5</sup>), anti-cardiolipin (P&#xa0;=&#xa0;0.002) and rheumatoid factor (P&#xa0;=&#xa0;0.004) and DRB1*13 with anti-Sm (P<sub>C</sub>=0.02) and anti-&#x3b2;2gpI (P<sub>C</sub>=0.01) antibodies. Also, negative associations of DRB1*04 with anti-Sm, anti-SSA/Ro, DQB1*03 with anti-Sm and DRB1*11 with anti-Sm and anti-&#x3b2;2gpI were observed.</AbstractText><AbstractText Label="CONCLUSIONS">We identified DRB1*03 and DRB1*16 as risk alleles and DRB1*01 as a potential protective allele for SLE disease. More importantly, we found a close link between genetic susceptibility for SLE and autoantibodies status that was more evident for DRB1*03 allele.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 European Federation of Immunological Societies. Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rasouli-Saravani</LastName><ForeName>Ashkan</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Immunology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tahamoli-Roudsari</LastName><ForeName>Ahmad</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Diseases Medicine, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Basiri</LastName><ForeName>Zahra</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Internal Diseases Medicine, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Babaei</LastName><ForeName>Mahboobeh</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Internal Diseases Medicine, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fazaeli</LastName><ForeName>Alireza</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Diseases Medicine, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roshanaei</LastName><ForeName>Ghodratollah</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biostatistics and Epidemiology, School of Health, Hamadan University of Medical Sciences, Hamadan, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hajilooi</LastName><ForeName>Mehrdad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Immunology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Solgi</LastName><ForeName>Ghasem</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Immunology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran; d. Psoriasis Research Center, Department of Dermatology, Farshchian Hospital, Hamadan University of Medical Sciences, Hamadan, Iran.. Electronic address: gh.solgi@umsha.ac.ir.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>06</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Immunol Lett</MedlineTA><NlmUniqueID>7910006</NlmUniqueID><ISSNLinking>0165-2478</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000974">Antibodies, Antinuclear</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001324">Autoantigens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D059866">HLA-DQ beta-Chains</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C069051">HLA-DQB1 antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D059811">HLA-DRB1 Chains</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000974" MajorTopicYN="N">Antibodies, Antinuclear</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001324" MajorTopicYN="N">Autoantigens</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005802" MajorTopicYN="Y">Genes, MHC Class II</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059866" MajorTopicYN="N">HLA-DQ beta-Chains</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059811" MajorTopicYN="N">HLA-DRB1 Chains</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006239" MajorTopicYN="N">Haplotypes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007492" MajorTopicYN="N" Type="Geographic">Iran</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="N">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Autoantibody</Keyword><Keyword MajorTopicYN="N">HLA-DQB1</Keyword><Keyword MajorTopicYN="N">HLA-DRB1</Keyword><Keyword MajorTopicYN="N">Systemic lupus erythematosus</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>9</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>6</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>6</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>6</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>6</Month><Day>29</Day><Hour>20</Hour><Minute>12</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34186156</ArticleId><ArticleId IdType="doi">10.1016/j.imlet.2021.06.004</ArticleId><ArticleId IdType="pii">S0165-2478(21)00098-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>